IP Library Granted Patent US 7,273,854
Granted Patent B1
US 7,273,854 · App. 09/578,453 · Granted Sep 25, 2007

Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,273,854
App. No.
09/578,453
Granted
Sep 25, 2007
Kind
B1
Abstract

The present invention relates to pharmaceutical compositions that act on the p53 protein or its gene and methods of use for the treatment of neurodegenerative diseases.

Claims (5)

1. A recombinant virus selected from the group consisting of adenovirus, adeno-associated virus and herpes virus, said recombinant virus comprising a nucleic acid consisting of:

(a) nucleic acids consisting of the sequence of SEQ ID NO:1 encoding an antisense RNA which inhibits expression of p53.

2. A method of inhibiting glutamate mediated ischemic neuronal cell death in cultured neuronal cells comprising: (a) administering to said cells a nucleic acid encoding an antisense RNA which inhibits expression of p53 wherein said nucleic acid has the sequence of SEQ ID NO: 1.

3. The method of claim 2 , wherein the nucleic acid is within a vector.

4. The method of claim 3 , wherein the vector is a replication defective virus.

Assignments (3)
CHANGE OF NAME Recorded Jun 13, 2007
From: RHONE-POULENC RORER S.A.
To: AVENTIS PHARMA S.A.
Reel/Frame 019418/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2007
From: MALLET, JACQUES; REVAH, FREDERIC; STUTZMANN, JEAN-MARIE
To: RHONE-POULENC RORER S.A.
Reel/Frame 019400/0130 →
CHANGE OF NAME Recorded Feb 28, 2001
From: RHONE-POULENC RORER S.A.
To: AVENTIS PHARMA S.A.
Reel/Frame 011566/0692 →